MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:28Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Leukotriene receptor antagonists]]
			[[Category:Antiasthmatic agents]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #20

2026-05-23T03:29:43Z

parser-claude batch MedTemplate pre-fill, Top 300 #20

New page

{{MedTemplate
| generic = Montelukast
| brand = Singulair
| structure =
| classes = [[:Category:Leukotriene_receptor_antagonists|Leukotriene receptor antagonist]], [[:Category:Antiasthmatic_agents|Antiasthmatic]]
| uses = <vote slug="asthma-controller-use">Asthma (controller)</vote>, <vote slug="eib-use">Exercise-induced bronchospasm</vote>, <vote slug="allergic-rhinitis-use">Allergic rhinitis</vote>
| starting_dose = 10 mg PO once daily in the evening (adults); 4-5 mg in children
| preparations = 10 mg tablets; 4 mg, 5 mg chewables; 4 mg granules
| fda_max = 10 mg/d (adults)
| pill_id =
| routes = Oral
| onset = Bronchodilation within 1-2 hours; full controller effect 1-2 weeks
| duration = 24 hours
| halflife = 2.7-5.5 hours<ref name="singulair-label">FDA Prescribing Information, Singulair (montelukast sodium), Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020829s072,020830s076,021409s050lbl.pdf</ref>
| bioavailability = ~64% (oral; not significantly affected by food)<ref name="singulair-label" />
| pregnancy = Generally considered safe; pregnancy registries do not show increased major malformation risk.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US. '''FDA Boxed Warning (2020):''' neuropsychiatric events including agitation, depression, sleep disturbance, and suicidal thoughts; benefit-risk should be reassessed regularly<ref name="singulair-label" />.
| mechanism = <vote slug="montelukast-mech-claim">Montelukast is a selective antagonist of the CysLT1 receptor; blocking leukotriene D4 (and to a lesser extent C4 and E4) binding reduces airway smooth muscle contraction, vascular permeability, and eosinophilic inflammation downstream of 5-lipoxygenase activation.</vote> Metabolized primarily via CYP2C8 with CYP3A4 contribution; the boxed warning was added after post-marketing reports of neuropsychiatric events were judged by FDA to outweigh the modest controller benefit relative to inhaled corticosteroids<ref name="singulair-label" />.
}}

== References ==
<references />

Montelukast - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #20